An Evaluation of Bone Mineral Density in HIV-1-infected Adult Subjects Switching From a Tenofovir-containing Antiretroviral Therapy Regimen to a Dolutegravir Plus Rilpivirine Regimen
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Dolutegravir/rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Registrational
- Sponsors ViiV Healthcare
- 26 Jul 2017 Primary endpoint (Percentage change from baseline at Week 48 in total hip BMD as assessed by areal density in gram per centimeter square (g/cm^2)) has been met, as per the results presented at the 9th International AIDS Society Conference on HIV Science.
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
- 27 Sep 2016 Planned End Date changed from 1 Sep 2018 to 1 Aug 2018.